Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
Holding APLS?
Track your performance easily
See the Price Targets and Ratings of:
APLS Analyst Ratings
Moderate Buy
12 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
APLS Stock 12 Month Forecast
Average Price Target
$45.86
▲(52.97% Upside)
| Highest Price Target$75.00 | Average Price Target$45.86 | Lowest Price Target$24.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Wells Fargo
Assigned
11/06/24
H.C. Wainwright
Reiterated
11/06/24
Goldman Sachs
Reiterated
11/06/24
Piper Sandler
Assigned
11/06/24
Scotiabank
Reiterated
11/06/24
Oppenheimer
Reiterated
11/06/24
Mizuho Securities
Initiated
11/06/24
Robert W. Baird
Reiterated
11/06/24
Needham
$85→$60
Buy
100.13%
Upside
Reiterated
11/05/24
Buy Rating for Apellis Pharmaceuticals: Confidence in Market Leadership and Potential Recovery
TD Cowen
$95→$60
Buy
100.13%
Upside
Reiterated
11/05/24
Apellis Pharmaceuticals: Long-Term Growth Potential for Syfovre Despite Short-Term Sales Challenges
Stifel Nicolaus
$84→$75
Buy
150.17%
Upside
Reiterated
11/05/24
Strategic Initiatives and Long-Term Growth Potential of Apellis Pharmaceuticals
J.P. Morgan
―
Buy
―
Reiterated
11/05/24
Confident Buy Rating for Apellis Pharmaceuticals: Navigating Challenges with Promising Long-term Growth Potential
Bank of America Securities
$47
Buy
56.77%
Upside
Reiterated
11/05/24
Apellis Pharmaceuticals (APLS) PT Lowered to $47 at BofA SecuritiesBofA Securities analyst Tazeen Ahmad lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $47.00 (from $61.00) while maintaining a Buy rating.
Best Analysts Covering Apellis Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy APLS and Sell After:
1 Month
xxx
Success Rate
20/31 ratings generated profit
Average Return
+4.43%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 64.52% of your transactions generating a profit, with an average return of +4.43% per trade.
3 Months
xxx
Success Rate
15/24 ratings generated profit
Average Return
+4.82%
reiterated a xxx
rating 9 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +4.82% per trade.
1 Year
Success Rate
15/29 ratings generated profit
Average Return
+8.26%
assigned a buy rating 4 days ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 51.72% of your transactions generating a profit, with an average return of +8.26% per trade.
2 Years
xxx
Success Rate
17/28 ratings generated profit
Average Return
+34.25%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.71% of your transactions generating a profit, with an average return of +34.25% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
APLS Analyst Recommendation Trends
Rating
Jul 24
Aug 24
Sep 24
Oct 24
Nov 24
Strong Buy
18
24
28
26
18
Buy
6
2
0
1
4
Hold
8
9
11
18
18
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
32
35
39
45
40
Each month's total comprises the sum of three months' worth of ratings.
APLS Financial Forecast
APLS Stock Forecast FAQ
What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is $45.86.
What is APLS’s upside potential, based on the analysts’ average price target?
Apellis Pharmaceuticals Inc has 52.97% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is APLS a Buy, Sell or Hold?
Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 12 buy ratings, 5 hold ratings and 0 sell ratings.
What is Apellis Pharmaceuticals Inc’s price target?
The average price target for Apellis Pharmaceuticals Inc is $45.86. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $75.00 ,the lowest forecast is $24.00. The average price target represents 52.97% Increase from the current price of $29.98.
The highest analyst price target is $75.00 ,the lowest forecast is $24.00. The average price target represents 52.97% Increase from the current price of $29.98.
What do analysts say about Apellis Pharmaceuticals Inc?
Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
How can I buy shares of APLS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.